

Resource Summary Report

Generated by [NIF](#) on Aug 30, 2026

Perkin Elmer: IVIS Spectrum In Vivo Imaging System

RRID:SCR_018621

Type: Tool

Proper Citation

Perkin Elmer: IVIS Spectrum In Vivo Imaging System (RRID:SCR_018621)

Resource Information

URL: <https://www.perkinelmer.com/product/ivis-instrument-spectrum-120v-andor-c-124262>

Proper Citation: Perkin Elmer: IVIS Spectrum In Vivo Imaging System (RRID:SCR_018621)

Description: In vivo imaging system that combines two dimensional and three dimensional optical tomography in one platform. The system uses leading optical technology for preclinical imaging research and development best for non-invasive longitudinal monitoring of disease progression, cell trafficking and gene expression patterns in living animals.

Resource Type: instrument resource

Keywords: In vivo imaging system, Instrument, Equipment, USEDit, Perkin Elmer, ABRF

Resource Name: Perkin Elmer: IVIS Spectrum In Vivo Imaging System

Resource ID: SCR_018621

Alternate IDs: Model_Number_IVIS, SCR_020397

Alternate URLs: https://resources.perkinelmer.com/lab-solutions/resources/docs/bro_010572b_01_prd_ivis_spectrum.pdf

Record Creation Time: 20220129T080341+0000

Record Last Update: 20260829T182548+0000

Ratings and Alerts

No rating or validation information has been found for Perkin Elmer: IVIS Spectrum In Vivo Imaging System.

No alerts have been found for Perkin Elmer: IVIS Spectrum In Vivo Imaging System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 47 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Brodsky AL, et al. (2026) Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(7), 1234.

O'Reilly C, et al. (2026) LRRC15-CAR T Cells for the Treatment of Osteosarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1557.

Ma B, et al. (2026) MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. *Molecular cancer research : MCR*.

Alsina M, et al. (2026) Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. *Cancer immunology research*, 14(4), 528.

Burchett R, et al. (2026) A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor. *Cancer immunology research*, 14(2), 261.

Young RG, et al. (2026) ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis. *Cancer research*, 86(14), 3502.

Pratt EC, et al. (2026) Trop-2-Directed Radioimmunotherapy with ¹⁷⁷Lu, ²²⁵Ac, and ²¹²Pb in a Pancreatic Cancer Model. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1462.

Akshatha CR, et al. (2026) Cancer Related Fatigue and its Association with Depression and Anxiety in the Patients with Advanced Gastric Cancer. *Journal of gastrointestinal cancer*, 57(1).

Adhikary U, et al. (2026) Cancer Susceptibility to Stapled Oncolytic Peptides Is Dictated by Membrane Cholesterol and Inflammatory Signaling. *Cancer research*, 86(11), 2810.

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. *Oncogene*, 45(4), 577.

Khan MA, et al. (2026) Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. *Cancer letters*, 638, 218160.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Laplante P, et al. (2025) Effect of MisMatch repair deficiency on metastasis occurrence in a syngeneic mouse model. *Neoplasia (New York, N.Y.)*, 62, 101145.

Kim BD, et al. (2025) Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models. *Journal of functional biomaterials*, 17(1).

Wang X, et al. (2025) Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor-Ligand Interactions That Instructs Intratumoral ??T-cell Activity. *Cancer research*, 85(2), 277.

Lee W, et al. (2025) Protocol for assessing mobilization of peritoneal B cells to the pre-metastatic omentum in an orthotopic mouse model of ovarian cancer. *STAR protocols*, 6(2), 103806.

Lindland K, et al. (2025) Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. *Molecular cancer therapeutics*, 24(9), 1415.

Bernasconi-Bisio F, et al. (2025) Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML. *Molecular therapy. Oncology*, 33(1), 200949.

Crawford KJ, et al. (2025) Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. *Molecular cancer*, 24(1), 208.

Harre P, et al. (2025) Dietary ?-3 polyunsaturated fatty acids (PUFAs) reduce cholesterol-driven non-small cell lung cancer (NSCLC) progression in mouse models of disease. *Communications medicine*, 5(1), 432.